126 related articles for article (PubMed ID: 38897411)
21. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
22. Impact of CYP2C19, CYP2C9, CYP3A4, and FMO3 Genetic Polymorphisms and Sex on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Chinese Subjects.
Liu S; Yao X; Tao J; Zhao S; Sun S; Wang S; Tian X
J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38654529
[TBL] [Abstract][Full Text] [Related]
23. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
24. Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole.
Mafuru M; Wu S; Mayala H; Msengwa Z; Phillip A; Mgone C
Pharmgenomics Pers Med; 2021; 14():1379-1389. PubMed ID: 34754219
[TBL] [Abstract][Full Text] [Related]
25. Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization.
Li S; Wu S; Gong W; Cao P; Chen X; Liu W; Xiang L; Wang Y; Huang J
Front Pharmacol; 2021; 12():730826. PubMed ID: 35046798
[No Abstract] [Full Text] [Related]
26. Optimization of Voriconazole Dosing Regimens Against Aspergillus Species and Candida Species in Pediatric Patients After Hematopoietic Cell Transplantation: A Theoretical Study Based on Pharmacokinetic/Pharmacodynamic Analysis.
Xie M; Jiang M; Qiu H; Rong L; Kong L
J Clin Pharmacol; 2023 Sep; 63(9):993-1001. PubMed ID: 37083934
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
[TBL] [Abstract][Full Text] [Related]
28. Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.
García-García I; Dapía I; Montserrat J; Martinez de Soto L; Bueno D; Díaz L; Queiruga J; Rodriguez Mariblanca A; Guerra-García P; Ramirez E; Frías J; Pérez Martínez A; Carcas-Sansuan AJ; Borobia AM
Front Pharmacol; 2021; 12():717932. PubMed ID: 34744712
[TBL] [Abstract][Full Text] [Related]
29. Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer.
Jainan W; Vilaichone RK
Asian Pac J Cancer Prev; 2014; 15(24):10957-60. PubMed ID: 25605208
[TBL] [Abstract][Full Text] [Related]
30. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.
Hicks JK; Crews KR; Flynn P; Haidar CE; Daniels CC; Yang W; Panetta JC; Pei D; Scott JR; Molinelli AR; Broeckel U; Bhojwani D; Evans WE; Relling MV
Pharmacogenomics; 2014 Jun; 15(8):1065-78. PubMed ID: 25084200
[TBL] [Abstract][Full Text] [Related]
31. Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.
Niioka T; Fujishima N; Abumiya M; Yamashita T; Ubukawa K; Nara M; Fujishima M; Takahashi N; Miura M
Ther Drug Monit; 2017 Oct; 39(5):514-521. PubMed ID: 28834922
[TBL] [Abstract][Full Text] [Related]
32.
Dai R; Zhao X; Zhuo H; Wang W; Xu Y; Hu Z; Zhang T; Zhao J
Front Cardiovasc Med; 2022; 9():1016126. PubMed ID: 36601065
[TBL] [Abstract][Full Text] [Related]
33. Effect of CYP2C19 polymorphism on the plasma voriconazole concentration and voriconazole-to-voriconazole-N-oxide concentration ratio in elderly patients.
Shang S; Cheng L; Li X; Xiang R; Yu M; Xiong L; Chen Y
Mycoses; 2020 Nov; 63(11):1181-1190. PubMed ID: 32416606
[TBL] [Abstract][Full Text] [Related]
34. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
[TBL] [Abstract][Full Text] [Related]
35. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
Lei HP; Wang G; Wang LS; Ou-yang DS; Chen H; Li Q; Zhang W; Tan ZR; Fan L; He YJ; Zhou HH
Ann Pharmacother; 2009 Apr; 43(4):726-31. PubMed ID: 19299322
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
37. Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole.
Aiuchi N; Nakagawa J; Sakuraba H; Takahata T; Kamata K; Saito N; Ueno K; Ishiyama M; Yamagata K; Kayaba H; Niioka T
Pharmacol Res Perspect; 2022 Apr; 10(2):e00935. PubMed ID: 35199485
[TBL] [Abstract][Full Text] [Related]
38. Impact of CYP2C19 metabolizer status on esophageal mucosal inflammation, acid exposure, and motility among patients on chronic proton-pump inhibitor therapy with refractory symptoms of gastroesophageal reflux disease.
Tai CC; Medwid S; Mclntosh K; Chande N; Kim RB; Gregor J
J Can Assoc Gastroenterol; 2024 Jun; 7(3):238-245. PubMed ID: 38841142
[TBL] [Abstract][Full Text] [Related]
39. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
Chuwongwattana S; Jantararoungtong T; Chitasombat MN; Puangpetch A; Prommas S; Dilokpattanamongkol P; Watcharananan SP; Sukasem C
Drug Metab Pharmacokinet; 2016 Apr; 31(2):117-22. PubMed ID: 26861072
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
